L. Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
L. Yang has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
A. Vuylsteke
Papworth Hospital Cambridge UK
1 shared publicationC. Gerrard
Papworth Hospital Cambridge UK
1 shared publicationC. McEniery
Experimental Medicine and Immunotherapeutics, Department of Medicine, Box 110, Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK
1 shared publicationI. B. Wilkinson
Experimental Medicine and Immunotherapeutics, Department of Medicine, Box 110, Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK
1 shared publication- Joseph Cheriyan
University of Cambridge
1 shared publication K. Mäki‐Petäjä
Experimental Medicine and Immunotherapeutics, Department of Medicine, Box 110, Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK
1 shared publication
Latest Publications
- Open Access
- 5 February 2015
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 80 (1) , 28-44
The role of epoxyeicosatrienoic acids in the cardiovascular system
There is increasing evidence suggesting that epoxyeicosatrienoic acids (EETs) play an important role in cardioprotective mechanisms. These include regulating vascular tone, modulating inflammatory responses, improving cardiomyocyte function and reducing ischaemic damage, resulting in attenuation of animal models of cardiovascular risk factors. This review discusses the current knowledge on the role of EETs in endothelium‐dependent control of vascular tone in the healthy and in subjects with cardiovascular risk factors, and considers the pharmacological potential of targeting this pathway.
- 5 February 2015
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 80 (1) , 28-44
Open AccessThe role of epoxyeicosatrienoic acids in the cardiovascular system
There is increasing evidence suggesting that epoxyeicosatrienoic acids (EETs) play an important role in cardioprotective mechanisms. These include regulating vascular tone, modulating inflammatory responses, improving cardiomyocyte function and reducing ischaemic damage, resulting in attenuation of animal models of cardiovascular risk factors. This review discusses the current knowledge on the role of EETs in endothelium‐dependent control of vascular tone in the healthy and in subjects with cardiovascular risk factors, and considers the pharmacological potential of targeting this pathway.